Cumulative Antibiotic Exposure Drives Multidrug-Resistant Organism Acquisition in Advanced Liver Disease
In patients with advanced chronic liver disease, cumulative antibiotic exposure drives the new acquisition of multidrug-resistant organisms, particularly vancomycin-resistant enterococci, according to a prospective cohort study published on October 9, 2026, in Clinical Infectious Diseases. Newly detected resistant bacteria during follow-up independently elevate the risk of 180-day mortality, whereas resistant organisms identified at baseline do not carry the same statistical hazard.
Study Design and Patient Cohort at the German Center
Researchers at Goethe University Frankfurt in Frankfurt am Main, Germany, led the study to quantify cumulative antibiotic exposure and its link to resistant bacteria and mortality. The analysis tracked 256 patients treated at the center between 2020 and 2023. The median age of the cohort was 59 years, and 68.8% of the participants were men. Investigators evaluated antibiotic exposure among 246 patients who showed no multidrug-resistant bacteria on their initial admission swab. Medical teams used oral and rectal screening swabs at admission, during every readmission, and whenever clinically indicated to detect resistant strains.
Acquisition Rates and Specific Dose Thresholds
During the follow-up period, 49 of the 246 patients, or 19.9%, acquired vancomycin-resistant enterococci, while 28 patients, or 11.4%, acquired resistant Gram-negative bacteria. The estimated risk threshold for acquiring vancomycin-resistant enterococci reached 20% at a cumulative total of 9.6 defined daily doses of any antibiotic. Lower amounts were required for specific drug classes to trigger that same 20% probability: 3.3 for carbapenems, 3.0 for cephalosporins, 1.5 for glycopeptides, and 3.6 for piperacillin-tazobactam. For Gram-negative multidrug-resistant bacteria, the 20% risk threshold required 19.2 defined daily doses of any antibiotic, 8.9 doses for beta-lactam/beta-lactamase inhibitor combinations, 9.9 for piperacillin-tazobactam, and 7.0 for carbapenems.
Mortality Risks Associated With Newly Detected Resistance
After adjusting for confounding factors, researchers found that newly detected resistant bacteria during follow-up correlated with a higher risk for 180-day mortality, yielding a hazard ratio of 2.15 with a P value of .004. In contrast, resistant bacteria detected on the first admission swab showed no independent association with 180-day mortality. Patients who acquired vancomycin-resistant enterococci demonstrated higher overall antibiotic exposure than those who remained free of the bacteria, measured by both defined daily doses and antibiotic use density.
Clinical Implications and Study Limitations
Myriam W. Heilani and colleagues noted that the findings point toward an exposure-aware strategy for managing decompensated cirrhosis. Cumulative exposure, rather than fixed treatment duration alone, should guide daily clinical decisions. Class-specific guidance should prompt timely reassessment, narrowing, or de-escalation of antimicrobial therapies. Study limitations include potential residual confounding from disease severity, as sicker patients received more antibiotics and underwent more frequent testing. Furthermore, antibiotics administered outside the study hospital went unrecorded, which may have led to an underestimation of total exposure, and the calculated dose thresholds originated from a single center and require validation in other healthcare settings.
Frequently Asked Questions About Antibiotic Exposure in Advanced Liver Disease
What specific antibiotic classes reached the 20% acquisition threshold at the lowest doses?
Glycopeptides reached the 20% risk threshold for vancomycin-resistant enterococci acquisition at just 1.5 defined daily doses, followed by cephalosporins at 3.0 doses and carbapenems at 3.3 doses.
How was cumulative antibiotic exposure measured in the Frankfurt study?
Researchers calculated exposure as the total in-hospital dose per patient up to the first detection of multidrug-resistant bacteria, or across the full follow-up period if no resistant bacteria appeared, measuring totals in defined daily doses and antibiotic use per 100 patient-days.
Which institutions and funding bodies supported the research?
Funding for the project was provided by the German Research Foundation, the Hessian Ministry of Higher Education, Research and the Arts, and the German Federal Ministry of Education and Research.